Form 4: Bristol-Myers Squibb Executive Cari Gallman Reports Stock Transactions

EVP Cari Gallman reports transactions involving Bristol-Myers Squibb (BMY) common stock and derivative securities, including vesting of market share units and performance shares.

Summary

• Cari Gallman, EVP of Corporate Affairs at Bristol-Myers Squibb, filed a Form 4 detailing changes in beneficial ownership of company stock.
• The transactions occurred on March 10, 2025, and involve common stock and derivative securities, specifically market share units and performance shares.
• Gallman acquired shares through the vesting of market share units and performance shares, and disposed of shares to cover tax obligations.
• The reported transactions resulted in Gallman holding 8,322 shares of common stock directly and various market share units and performance shares that will convert into common stock in the future.
• The market share units convert into common stock based on a payout factor tied to the company's stock price performance.
• Performance shares convert into one share of common stock upon distribution, subject to performance results certified by the Board.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices and compliance with SEC regulations. The vesting of equity awards suggests positive performance, contributing to a moderately positive sentiment.

Positives

• The vesting of market share units and performance shares indicates that performance targets were met, which is a positive sign for the company.
• The executive's continued holding of a significant number of shares aligns their interests with those of shareholders.

Negatives

• The disposal of shares to cover tax obligations, while standard practice, slightly reduces the executive's stake in the company.

Risks

• The value of market share units and performance shares is dependent on the company's future stock price performance, which is subject to market risks.
• Changes in company performance or market conditions could impact the payout factor and the number of shares ultimately received.

Future Outlook

The document outlines future vesting dates for market share units and performance shares, contingent on company performance and board certification.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. This filing indicates that the executive is receiving compensation in the form of equity, aligning their interests with shareholders.

Comparison to Industry Standards

• Equity-based compensation, including market share units and performance shares, is a common practice among large pharmaceutical companies like Bristol-Myers Squibb to incentivize executives and align their interests with long-term shareholder value.
• Companies like Johnson & Johnson and Pfizer also utilize similar compensation structures, with vesting schedules and performance metrics tied to company performance.
• The specific payout factors and performance metrics used by Bristol-Myers Squibb are likely benchmarked against industry peers to ensure competitiveness and effectiveness.

Stakeholder Impact

• Shareholders can gain insight into executive compensation and alignment of interests through this filing.
• Employees may be impacted by the company's performance, which affects the value of equity-based compensation.

Next Steps

• Future vesting of market share units and performance shares will occur on the dates specified in the document, subject to performance conditions and board certification.

Key Dates